Fraunhoferstraße 22
82152 Martinsried
Germany
Phone: +49 89 899 59 400
www.xantos-bio.de

Peter Buckel,CEO
Privately Held

Overview

Xantos Biomedicine GmbH, founded in 1999, is a biotech company focusing on functional genomics. Using its XantoScreen high-throughput system, Xantos defines the function of human genes relevant for diagnostic and therapeutic interventions of human diseases for internal product development and commercial collaboration in areas such as degenerative diseases, oncology, organ/tissue formation and obesity.

Xantos’ target and drug discovery program focuses on apoptosis using XantoScreen, which systematically searches the genome to identify genes that will trigger cell death only in tumor cells. XantoScreen also is being used to discover genetic functions that are involved in cell differentiation to find the genes responsible for controlling the complex sequence of signals generated when stem cells develop into differentiated cells.

Xantos plans to develop biopharmaceutical projects into the early clinical phase. Low-molecular-weight drugs and diagnostic candidates will be licensed early in development. To expand the screening of medically relevant gene functions and to accelerate the initiation of diagnostic and therapeutic product developments, Xantos also is aiming to initiate new strategic alliances with complementary biotech companies and academic institutions.

The company expects to screen the human genome in a variety of biological functions. All data will be stored in a knowledge database allowing for the correlation of gene sequences and function. Partners will get access to this database, allowing them to check whether those biological functions are involved in processes of interest to their internal research.

Partners

Research two newly discovered genes inducing programmed cell death recently identified by Xantos: Xerion Pharmaceuticals AG.

Apoptosis gene identification in breast, bowel and prostate cancers: Ministry of Education and Research of Germany and the Univeristy of Tübingen.

Other partners include the Max Planck Institute for Biochemistry, Max Planck Institute for Psychiatry, Freie Universit t Berlin, the University of Würzburg, F. Hoffmann-La Roche Ltd. and mice & more GmbH & Co. KG.